tetano
Editor, Senior Moderator
J Infect Chemother
. 2024 Feb 9:S1341-321X(24)00034-5.
doi: 10.1016/j.jiac.2024.02.004. Online ahead of print. Detailed tracking of antigen and antibody levels during coronavirus disease 2019 treatment in an immunosuppressed patient with anti-neutrophil cytoplasmic autoantibody-associated vasculitis
Toshitaka Yukishima[SUP] 1 [/SUP], Kazuki Furuhashi[SUP] 2 [/SUP], Kumiko Shimoyama[SUP] 3 [/SUP], Takeru Taki[SUP] 4 [/SUP], Chika Azuma[SUP] 5 [/SUP], Kenji Yamazaki[SUP] 6 [/SUP], Shogo Furukawa[SUP] 7 [/SUP], Soma Fukami[SUP] 8 [/SUP], Osanori Nagura[SUP] 9 [/SUP], Kazuto Katahashi[SUP] 10 [/SUP], Keita Yamashita[SUP] 11 [/SUP], Masato Maekawa[SUP] 12 [/SUP], Noriyoshi Ogawa[SUP] 13 [/SUP]
Affiliations
A 67-year-old woman with anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis was not vaccinated against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and was on multiple immunosuppressive drugs. She was hospitalized because of interstitial shadowing in the lungs and diagnosed with persistent coronavirus disease 2019 (COVID-19). Despite treatment with a recombinant monoclonal antibody and antivirals, her symptoms persisted and she lacked a specific antibody response. She tested negative for SARS-CoV-2 antigen after the second antiviral treatment, and a subsequent chest radiograph showed improvement. However, the antibody levels did not change. This case highlights the importance of careful monitoring of the SARS-CoV-2 antigen and antibody levels during COVID-19 treatment in patients with immunosuppression.
Keywords: Coronavirus disease 2019; Nirmatrelvir/ritonavir; SARS-CoV-2 antibody; SARS-CoV-2 antigen; anti-neutrophil cytoplasmic antibody-associated vasculitis; sotrovimab.
. 2024 Feb 9:S1341-321X(24)00034-5.
doi: 10.1016/j.jiac.2024.02.004. Online ahead of print. Detailed tracking of antigen and antibody levels during coronavirus disease 2019 treatment in an immunosuppressed patient with anti-neutrophil cytoplasmic autoantibody-associated vasculitis
Toshitaka Yukishima[SUP] 1 [/SUP], Kazuki Furuhashi[SUP] 2 [/SUP], Kumiko Shimoyama[SUP] 3 [/SUP], Takeru Taki[SUP] 4 [/SUP], Chika Azuma[SUP] 5 [/SUP], Kenji Yamazaki[SUP] 6 [/SUP], Shogo Furukawa[SUP] 7 [/SUP], Soma Fukami[SUP] 8 [/SUP], Osanori Nagura[SUP] 9 [/SUP], Kazuto Katahashi[SUP] 10 [/SUP], Keita Yamashita[SUP] 11 [/SUP], Masato Maekawa[SUP] 12 [/SUP], Noriyoshi Ogawa[SUP] 13 [/SUP]
Affiliations
- PMID: 38342142
- DOI: 10.1016/j.jiac.2024.02.004
A 67-year-old woman with anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis was not vaccinated against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and was on multiple immunosuppressive drugs. She was hospitalized because of interstitial shadowing in the lungs and diagnosed with persistent coronavirus disease 2019 (COVID-19). Despite treatment with a recombinant monoclonal antibody and antivirals, her symptoms persisted and she lacked a specific antibody response. She tested negative for SARS-CoV-2 antigen after the second antiviral treatment, and a subsequent chest radiograph showed improvement. However, the antibody levels did not change. This case highlights the importance of careful monitoring of the SARS-CoV-2 antigen and antibody levels during COVID-19 treatment in patients with immunosuppression.
Keywords: Coronavirus disease 2019; Nirmatrelvir/ritonavir; SARS-CoV-2 antibody; SARS-CoV-2 antigen; anti-neutrophil cytoplasmic antibody-associated vasculitis; sotrovimab.